0001494891
false
0001494891
2023-08-03
2023-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 3, 2023
SENSUS HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-37714 |
|
27-1647271 |
(State of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
851 Broken Sound
Pkwy., NW # 215, Boca Raton, Florida |
|
33487 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (561) 922-5808
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
Common Stock, par value $0.01 per share |
|
SRTS |
|
Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SENSUS HEALTHCARE, INC.
FORM 8-K
CURRENT REPORT
Item 2.02 | Results of Operation and Financial Condition |
On August 3, 2023, Sensus Healthcare, Inc. announced via press release
its financial results for the second quarter of 2023. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form
8-K and incorporated herein by reference.
The press release makes reference to certain non-GAAP financial measures.
A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.
The information furnished under Item 2.02, including in Exhibit 99.1,
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
SENSUS HEALTHCARE, INC. |
|
|
Date: August 3, 2023 |
By: |
/s/ Javier
Rampolla |
|
|
Javier Rampolla |
|
|
Chief Financial Officer |
EXHIBIT INDEX
3
Exhibit 99.1
Sensus
Healthcare Reports Second Quarter 2023 Financial Results
| ● | Revenues
increased 33% and system shipments increased 30%, both compared with the first quarter of
2023 |
| | |
| ● | Achieved
a milestone with the installation of 700 systems for a total of 708 |
| | |
| ● | Expects
to ship at least 60 SRT units during 2023 and to return to profitability in the second half
of the year |
Conference
call begins at 4:30 p.m. Eastern time today
BOCA
RATON, Fla. (August 3, 2023) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,
non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results
for the three and six months ended June 30, 2023.
Highlights
from the second quarter of 2023 and recent weeks include the following:
| ● | Achieved
revenues of $4.5 million, an increase of 33% from $3.4 million for the first quarter of 2023
and a decrease from $12.1 million in the prior-year quarter reflecting lower SRT unit sales |
| | |
| ● | Shipped
13 SRT systems including four outside the U.S. and six SRT-100 Vision™ systems, an
increase from 10 systems shipped during the first quarter of 2023 and a decrease from 33
systems shipped in the prior-year quarter |
| | |
| ● | Surpassed
700 total systems, with 708 sold worldwide. |
| | |
| ● | Narrowed
the net loss to $0.4 million, or $0.02 per share, from a net loss of $1.9 million, or $0.12
per share, for the first quarter of 2023 and versus net income of $3.5 million, or $0.21
per diluted share, for the prior-year quarter |
| | |
| ● | Ended
the quarter with $20.1 million in cash and cash equivalents, and no debt |
| | |
| ● | Sold
the first SRT System in Ireland, to Dublin’s Beacon Hospital |
| | |
| ● | Engaged
MIS Healthcare to distribute SRT systems in the United Kingdom and Ireland |
| | |
| ● | Anticipates
profitability for the second half of the year based on a growing number of prospects |
Management
Commentary
“Many
of our customers depend on elective aesthetic procedures as a meaningful source of practice revenue and profit, and we are hearing encouraging
feedback that patient volumes and procedure mix are improving. Our second quarter financial results reflect that dynamic and strengthened
considerably compared with the first quarter,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We
expect to return to profitability in the second half of the year as these trends continue. In preparation, we continued to build inventory
and prepay for components.
“International
expansion is an important strategic goal and we were delighted to enter into a new partnership with MIS Healthcare to distribute SRT
systems in the United Kingdom and British Isles. Prior to that engagement our internal sales staff had been working for several months
with Beacon Hospital in Dublin, and we were delighted to have installed an SRT unit there during recent weeks. We believe Ireland holds
excellent promise for SRT, with 600 people diagnosed with non-melanoma skin cancer each day. We also sold an SRT-100 System to a hospital
in Guatemala as we advance our efforts in Latin America.
“Our
plan is to enter three to four new territories over the coming years, and we are advancing this goal with sales to Southeast Asia
and Latin America, in addition to the UK and Ireland. We are regaining momentum in China now that pandemic lockdowns have been
lifted and shipped two SRT systems there during the second quarter, for a total of five shipments to Asia so far this
year.
“Sentinel
IT is our HIPAA-compliant software that stores patient data for multiple clinical purposes and will include artificial intelligence to
allow customers to better manage their practices and data. Sentinel IT is expected to play a key role in our growth, and during the quarter
we launched our Sentinel/Sensus Cloud capabilities at the American Academy of Dermatology Annual Meeting. We look forward to showcasing
Sentinel IT and our SRT products at local dermatology trade shows, as well as at the American Society for Radiation Oncology beginning
October 1st. Although the hospital market has a longer sales cycle, radiation oncology is a highly attractive opportunity
as their interest expands to skin cancer.”
Mr.
Sardano concluded, “With an estimated one in five Americans, or 70 million people expected to develop skin cancer during their
lifetime, SRT is the No. 1 choice for the non-invasive treatment of non-melanoma skin cancer. SRT treatments surpassed 480,000 in the
last two years alone and the ROI for our premium SRT system under our fair market value leasing program continues to be compelling, with
breakeven at only 2 to 2.5 patients per month. Surveys of Medicare show that SRT has experienced a 27% treatment growth rate year over
year for the past six years. If this growth utilization rate continues at its current pace, SRT will soon become the treatment of choice
for non-melanoma skin cancer. Accordingly, professional interest in SRT remains high, and we expect to meet our objectives of shipping
at least 60 SRT systems during 2023 and returning to profitability in the second half of the year.”
Second
Quarter Financial Results
Revenues
for the second quarter of 2023 were $4.5 million, compared with $12.1 million for the second quarter of 2022. The decrease was primarily
due to a lower number of SRT units sold as customers continued to defer purchases, as well as to lower sales to a large customer.
Cost
of sales was $1.9 million for the second quarter of 2023, compared with $3.8 million for the prior-year quarter. The decrease was primarily
due to lower sales in the second quarter of 2023.
Gross
profit for the second quarter of 2023 was $2.6 million, or 57.9% of revenues, compared with $8.3 million, or 68.3% of revenues, for the
second quarter of 2022. The decrease was primarily due to the lower number of units sold and higher costs charged by vendors in the 2023
quarter.
Selling
and marketing expense was $1.6 million for the second quarter of 2023, compared with $1.7 million for the prior-year quarter. The decrease
was primarily attributable to a decrease in marketing initiatives and commissions, partially offset by an increase in headcount costs.
General
and administrative expense was $1.3 million for the second quarter of 2023, compared with $1.1 million for the second quarter of 2022.
The increase was primarily due to higher professional fees, offset by a reduction in insurance expense.
Research
and development expense was $0.8 million for the second quarter of 2023, unchanged from the comparable 2022 period.
Other
income of $0.2 million for the second quarter of 2023 was related to interest income.
Net
loss for the second quarter of 2023 was $0.4 million, or $0.02 per share, compared with net income of $3.5 million, or $0.21 per diluted
share, for the second quarter of 2022.
Adjusted
EBITDA for the second quarter of 2023 was negative $1.0 million, compared with positive $4.7 million for the second quarter of 2022.
Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation
expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial
measures are provided.
Cash
and cash equivalents were $20.1 million as of June 30, 2023, compared with $25.5 million as of December 31, 2022. The Company had no
outstanding borrowings under its revolving line of credit as of June 30, 2023 or December 31, 2022. Prepaid and other current assets
were $8.1 million as of June 30, 2023, compared with $6.9 million as of December 31, 2022. Inventories were $10.1 million as of June
30, 2023, compared with $3.5 million as of December 31, 2022, with the increase reflecting the Company’s expectations for higher
unit sales during the second half of the year.
Six
Month Financial Results
Revenues
were $7.9 million for the first half of 2023, compared with $22.4 million for the first half of 2022, reflecting a lower number of units
sold.
Cost
of sales was $3.7 million for the first half of 2023, compared with $7.0 million for the first half of 2022. The decrease was primarily
related to lower sales in the first half of 2023.
Gross
profit was $4.2 million for the first half of 2023, or 53.4% of revenues, compared with $15.4 million, or 68.7% of revenues, for the
first half of 2022. The decrease in gross profit was primarily driven by the lower number of units sold and higher costs charged by vendors
in the first half of 2023.
Selling
and marketing expense was $3.7 million for the first half of 2023, compared with $2.9 million for the first half of 2022. The increase
was primarily attributable to an increase in tradeshow expense and headcount costs, partially offset by a decrease in commissions.
General
and administrative expense was $2.7 million for the first half of 2023, compared with $2.4 million for the first half of 2022. The increase
was primarily due to higher professional fees, offset by a reduction in insurance expense.
Research
and development expense was $1.9 million for the first half of 2023, compared with $1.6 million for the first half of 2022. The increase
was primarily due to expenses related to a project to develop a drug-delivery system for aesthetic use. The Company expects to complete
this project by the end of 2023.
Other
income of $0.5 million for the first half of 2023 was related to interest income. Other income of $12.8 million for the first half of
2022 was related to the gain on the sale of a non-core asset.
Net
loss for the first half of 2023 was $2.3 million, or $0.14 per share, compared with net income of $19.6 million, or $1.17 per diluted
share, for the first half of 2022. Net income for the 2022 period includes a $12.8 million gain on the sale of a non-core asset.
Adjusted
EBITDA for the first half of 2023 was negative $3.7 million, compared with positive $21.5 million for the first half of 2022.
Use
of Non-GAAP Financial Information
This
press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally
accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis
of the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed
as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which
excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental
information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are
not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement
to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts
who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation
of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.
SENSUS
HEALTHCARE, INC.
GAAP
TO NON-GAAP RECONCILIATION
(unaudited)
| |
For the Three Months Ended | | |
For the Six Months Ended | |
| |
June 30, | | |
June 30, | |
(in thousands) | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Net income, as reported | |
$ | (380 | ) | |
$ | 3,524 | | |
$ | (2,274 | ) | |
$ | 19,586 | |
Add: | |
| | | |
| | | |
| | | |
| | |
Depreciation and amortization | |
| 84 | | |
| 74 | | |
| 155 | | |
| 166 | |
Stock compensation expense | |
| 67 | | |
| 40 | | |
| 209 | | |
| 97 | |
Income tax expense (benefit) | |
| (502 | ) | |
| 1,070 | | |
| (1,303 | ) | |
| 1,718 | |
Interest income, net | |
| (245 | ) | |
| (24 | ) | |
| (488 | ) | |
| (27 | ) |
Adjusted EBITDA, non GAAP | |
$ | (976 | ) | |
$ | 4,684 | | |
$ | (3,701 | ) | |
$ | 21,540 | |
Conference
Call and Webcast
Sensus
Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss
financial results for the 2023 second quarter, provide a business update and answer questions. To access the conference call, dial 844-481-2811
(U.S. and Canada Toll Free) or 412-317-0676 (International). The call will be webcast live and can be accessed at this link, or in the
Investors section of the Company’s website at www.sensushealthcare.com.
Following
the conclusion of the conference call, a replay will be available until September 3, 2023 and can be accessed by dialing 877-344-7529
(U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 1356425. An archived webcast of
the call will also be available in the Investors section of the Company’s website.
About
Sensus Healthcare
Sensus
Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments
for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation
therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids
with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative
medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides
revolutionary treatment options to enhance the quality of life of patients around the world.
For
more information, visit www.sensushealthcare.com.
Forward-Looking
Statements
This
press release includes statements that are, or may be deemed, ’‘forward-looking statements.’’ In some cases, these statements can be
identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should,”
“approximately,” “potential” or negative or other variations of those terms or comparable terminology, although
not all forward-looking statements contain these words.
Forward-looking
statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our
industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter
timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and
our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may
differ materially from the forward looking statements contained in this press release, as a result of the following factors, among
others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023;
the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third
party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our
products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to
efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign
countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation,
or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one
particular customer in the U.S.; our ability to obtain and maintain the intellectual property needed to adequately protect our
products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other
risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q.
To
date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have had any particular impact on our
business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In
addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this
press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in
this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events
or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory
Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports
filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim
Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
(Tables
to follow)
SENSUS
HEALTHCARE, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
| |
For the Three Months Ended | | |
For the Six Months Ended | |
(in thousands, except share and per share data) | |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
(unaudited) | | |
(unaudited) | | |
(unaudited) | | |
(unaudited) | |
Revenues | |
$ | 4,527 | | |
$ | 12,080 | | |
$ | 7,941 | | |
$ | 22,417 | |
Cost of sales | |
| 1,908 | | |
| 3,824 | | |
| 3,700 | | |
| 7,013 | |
Gross profit | |
| 2,619 | | |
| 8,256 | | |
| 4,241 | | |
| 15,404 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Selling and marketing | |
| 1,595 | | |
| 1,728 | | |
| 3,693 | | |
| 2,946 | |
General and administrative | |
| 1,329 | | |
| 1,131 | | |
| 2,693 | | |
| 2,404 | |
Research and development | |
| 822 | | |
| 827 | | |
| 1,920 | | |
| 1,556 | |
Total operating expenses | |
| 3,746 | | |
| 3,686 | | |
| 8,306 | | |
| 6,906 | |
Income (loss) from operations | |
| (1,127 | ) | |
| 4,570 | | |
| (4,065 | ) | |
| 8,498 | |
Other income: | |
| | | |
| | | |
| | | |
| | |
Gain on sale of assets | |
| - | | |
| - | | |
| - | | |
| 12,779 | |
Interest income | |
| 245 | | |
| 24 | | |
| 488 | | |
| 27 | |
Other income | |
| 245 | | |
| 24 | | |
| 488 | | |
| 12,806 | |
Net Income (loss) before income tax | |
| (882 | ) | |
| 4,594 | | |
| (3,577 | ) | |
| 21,304 | |
Provision for (benefit from) income tax | |
| (502 | ) | |
| 1,070 | | |
| (1,303 | ) | |
| 1,718 | |
Net Income (loss) | |
$ | (380 | ) | |
$ | 3,524 | | |
$ | (2,274 | ) | |
$ | 19,586 | |
Net income (loss) per share – basic | |
$ | (0.02 | ) | |
$ | 0.21 | | |
$ | (0.14 | ) | |
$ | 1.19 | |
– diluted | |
$ | (0.02 | ) | |
$ | 0.21 | | |
$ | (0.14 | ) | |
$ | 1.17 | |
Weighted average number of shares used in computing net income (loss) per share – basic | |
| 16,249,766 | | |
| 16,495,043 | | |
| 16,247,567 | | |
| 16,508,629 | |
– diluted | |
| 16,249,766 | | |
| 16,631,478 | | |
| 16,247,567 | | |
| 16,710,550 | |
SENSUS
HEALTHCARE, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
| |
As of
June 30, | | |
As of
December 31, | |
(in thousands, except shares and per share data) | |
2023 | | |
2022 | |
| |
(unaudited) | | |
| |
Assets | |
| | |
| |
Current assets | |
| | |
| |
Cash and cash equivalents | |
$ | 20,053 | | |
$ | 25,520 | |
Accounts receivable, net | |
| 9,149 | | |
| 17,299 | |
Inventories | |
| 10,131 | | |
| 3,501 | |
Prepaid and other current assets | |
| 8,059 | | |
| 6,921 | |
Total current assets | |
| 47,392 | | |
| 53,241 | |
Property and equipment, net | |
| 367 | | |
| 243 | |
Intangibles, net | |
| 1 | | |
| 50 | |
Deposits | |
| 24 | | |
| 24 | |
Deferred tax asset | |
| 3,017 | | |
| 1,713 | |
Operating lease right-of-use assets, net | |
| 866 | | |
| 996 | |
Other noncurrent assets | |
| 350 | | |
| 468 | |
Total assets | |
$ | 52,017 | | |
$ | 56,735 | |
Liabilities and stockholders’ equity | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 3,941 | | |
$ | 5,521 | |
Product warranties | |
| 379 | | |
| 403 | |
Operating lease liabilities, current portion | |
| 181 | | |
| 190 | |
Income tax payable | |
| - | | |
| 890 | |
Deferred revenue, current portion | |
| 692 | | |
| 693 | |
Total current Liabilities | |
| 5,193 | | |
| 7,697 | |
Operating lease liabilities, net of current portion | |
| 698 | | |
| 830 | |
Deferred revenue, net of current portion | |
| 116 | | |
| 139 | |
Total liabilities | |
| 6,007 | | |
| 8,666 | |
Commitments and contingencies | |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred stock, 5,000,000 shares authorized and none issued and outstanding | |
| - | | |
| - | |
Common stock, $0.01 par value – 50,000,000
authorized; 16,912,595 issued and 16,395,766 outstanding at June 30, 2023; 16,902,761 issued and 16,390,419 outstanding at December
31, 2022 | |
| 169 | | |
| 169 | |
Additional paid-in capital | |
| 45,286 | | |
| 45,031 | |
Treasury stock, 516,829 and 512,342 shares at cost, at
June 30, 2023 and December 31, 2022, respectively | |
| (3,473 | ) | |
| (3,433 | ) |
Retained earnings | |
| 4,028 | | |
| 6,302 | |
Total stockholders’ equity | |
| 46,010 | | |
| 48,069 | |
Total liabilities and stockholders’ equity | |
$ | 52,017 | | |
$ | 56,735 | |
#
# #
7
v3.23.2
Cover
|
Aug. 03, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 03, 2023
|
Entity File Number |
001-37714
|
Entity Registrant Name |
SENSUS HEALTHCARE, INC.
|
Entity Central Index Key |
0001494891
|
Entity Tax Identification Number |
27-1647271
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
851 Broken Sound
Pkwy.
|
Entity Address, Address Line Two |
NW # 215
|
Entity Address, City or Town |
Boca Raton
|
Entity Address, State or Province |
FL
|
Entity Address, Postal Zip Code |
33487
|
City Area Code |
561
|
Local Phone Number |
922-5808
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
Trading Symbol |
SRTS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Sensus Healthcare (NASDAQ:SRTS)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Sensus Healthcare (NASDAQ:SRTS)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024